Nurix Therapeutics is trading at $23.09, up 4.36%, following its October 13 report, which showed $673.1 million in revenue, largely from Roche collaboration revenue.
- The report also showed $549.8 million in net income.
- Analysts made mixed price-target changes; Stifel raised its target to $41 and maintained Buy.
- Broader markets and biotech were weaker and do not explain the gain; no specific intraday volume data was available.